7 results about "Phosphate binding agents" patented technology

Compositions and principles for use before parturition in the prophylactic treatment of hypocalcemia in ruminant animals include compositions having phosphate binders for the prophylactic treatment of parturient hypocalcemia in ruminant animals. These compositions are presented in unit dosage forms, with one or more doses administered daily to the gastrointestinal tract of the ruminant animal, or in wet form. The composition contains one or more phosphate binders and one or more nutrients selected from minerals, vitamins, and amino acids, as well as a composition that includes an inhibitor of the small intestinal Na-phosphate transporter for the prophylactic treatment of parturient hypocalcemia in ruminant animals. Phosphate binders are selected from aluminum, iron, sevelamer, and lanthanum salts, with either inorganic or organic acids, hydrates thereof, or any mixture thereof.

The invention belongs to the field of phosphate binders, and relates to a straight-chain saturated aliphatic dicarboxylic acid-iron (III) compound, a preparation method and application thereof, in particular to application of the straight-chain saturated aliphatic dicarboxylic acid-iron (III) compound in preparation of drugs for treating or preventing hyperphosphatemia. The molar ratio of iron element to dicarboxylic acid in the dicarboxylic acid-iron (III) compound is 1: (0.8-1.2), the dicarboxylic acid is straight-chain saturated aliphatic dicarboxylic acid, and the compound is prepared by reacting ferric salt and dicarboxylate in a solvent. An in-vitro phosphorus binding experiment proves that the dicarboxylic acid-iron (III) compound disclosed by the invention is high in phosphorus binding amount of iron per unit mass in a pH range of 3-7, can also keep very high phosphorus binding capacity of iron per unit mass in an animal body, and is obviously superior to commercially available sucrose iron oxyhydroxide chewable tablets. As an oral phosphorus binding agent, the compound disclosed by the invention is stronger in phosphorus binding capacity of unit mass of iron in vivo, high in iron utilization rate, small in total dosage of iron element and lower in adverse reaction.

The invention provides a baking-free prefabricated part for a rotary kiln and a preparation method of the baking-free prefabricated part. The baking-free prefabricated part for the rotary kiln is prepared from the following raw materials in parts by mass: 35-50 parts of fused magnesite, 20-40 parts of magnesium aluminate spinel, 0.5-5 parts of silica powder, 0.5-5 parts of silicon nitride fine powder, 1-6 parts of zirconium titanate, 1-6 parts of aluminum oxide hollow spheres, 1-8 parts of a phosphate binding agent and 1-6 parts of a water reducing agent. The baking-free prefabricated part for the rotary kiln has good strength performance, lower heat conductivity and better cement clinker corrosion resistance.

The present invention is related to a novel pharmaceutical product containing iron and meglumine. In certain embodiments, the present invention is related to a novel injectable dosage form comprising ferric meglumine as a parenteral iron supplement to treat iron deficiency anemia. In certain embodiments, the present invention is related to a novel oral dosage form comprising ferric meglumine as iron supplement and / or phosphate binder.

The present invention provides methods and pharmaceutical compositions for reducing serum phosphate levels in mammals and humans comprising the combined use of component (a) a phosphate binder; and component (b) a phosphate transport inhibitor, wherein a therapeutically effective amount of at least one of the component (a) and component (b) administered to the subject is lower than a therapeutically effective amount of the component administered in the absence of the other component.

The invention relates to the technical field of refractory bricks, in particular to a phosphate combined light-burned high-alumina brick for a high-erosion-resistance Mannheim furnace hearth, which is prepared from the following raw materials in parts by weight: 30 to 35 parts of homogenized alumina, 35 to 40 parts of calcined alumina, 8 to 10 parts of ball clay, 1.5 to 2 parts of mixed liquor, 4 to 6 parts of aluminum dihydrogen phosphate solution and 10 to 15 parts of filler. According to the invention, after zircon in the base material is activated by dilute nitric acid and modified by a silane coupling agent, the surface activity is improved, the zircon and a phosphate binding agent generate strong chemical bonding, nano zirconium oxide in the auxiliary material forms a stable crystal structure after hydrothermal synthesis and high-temperature calcination, and the base material and the auxiliary material are tightly combined in the mixing process; uniformly distributed reinforcing units are formed in the matrix, and through double mechanisms of physical filling and interface chemical bonding, the densification degree and integrity of the matrix are remarkably improved, so that the permeation path of a corrosive medium is effectively blocked, and the long service life of the material is ensured.

The present invention provides methods and pharmaceutical compositions for reducing serum phosphate levels in mammals and humans comprising the combined use of component (a) a phosphate binder; and component (b) a phosphate transport inhibitor.